Analystreport

Akero Therapeutics (NASDAQ: AKRO) had its "buy" rating re-affirmed by analysts at Canaccord Genuity.

Akero Therapeutics, Inc.  (AKRO) 
Last akero therapeutics, inc. earnings: 3/16 07:30 am Check Earnings Report